Yesterday, Arno Therapeutics, Inc. announced that Alexander Zukiwski, M.D. has been appointed as its Chief Medical Officer. He will be responsible for leading the clinical development and regulatory affairs teams supporting Arno’s current and future pipeline of innovative cancer therapies.

Most recently, Dr. Zukiwski served as the Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc. where he led an organization that was responsible for developing and implementing MedImmune’s clinical research, medical affairs and safety strategies. Prior to MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development.

As Vice President, Head of Clinical Oncology, Dr. Zukiwski supervised the strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for JJPRD and Centocor’s oncology development group. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer.

Dr. Zukiwski received a bachelor’s degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas, M.D. Anderson Cancer Center.

“Alex has an impressive record of success in the strategic and operational execution of clinical studies and regulatory submissions of many therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis® and Doxil®,” said Glenn Mattes, President and Chief Executive Officer of Arno. “His expertise in global oncology drug development will be invaluable as we pursue potential new indications for our product candidates and advance our pipeline of anti-cancer agents towards registration. We are pleased to welcome him to Arno and look forward to his contributions to our future success.”

On his new position, Dr. Zukiwski remarked, “I am excited to work with my former colleague, Glenn Mattes, and the Arno Therapeutics team to successfully advance our pipeline of innovative cancer therapies. I believe that Arno’s compounds have the ability to become important products in the future of oncology treatment and that our team can drive the commercialization of these exciting agents.”